InvestorWire NewsRoom

Article

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing
May 17, 2022

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing

  • Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio 
  • The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental health
  • The company’s goal is to expand its clinic offering to 60-70% of the American population driving no more than 45-minutes to reach a clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, is committed to bringing the science-backed benefits of psychedelics to more people and reframing the conversations about them. The company owns and operates an assortment of related businesses, including two media platforms (Reality Sandwich and Delic Radio), a Health Canada-licensed entity focusing on the research and development of psilocybin vaporization technology (Delic Labs), a premier psychedelic wellness event (Meet Delic), and the largest network of ketamine clinics in the country (Ketamine Wellness Centers). Delic is backed by a team of industry and cannabis veterans who, alongside a diverse network, share a mission to provide education, research, high-quality products, and treatment options to the population. 

The company is uniquely positioned to capitalize on the psychedelic drugs market, an expanding sector whose growth is primarily driven by an increased acceptance of psychedelics use for mental health. According to Data Bridge Market Research, the psychedelic drugs market was valued at US $2,834.72 million in 2021. The market is expected to grow at a CAGR of 16.8%, resulting in a value of US $9,818.68 million by 2029 (https://ibn.fm/VRf9G).

Delic Holdings company has received a Health Canada 56 Health Exemption, which allows Delic’s scientists to do research with numerous compounds outside of psychedelic mushrooms, including MDMA (ecstasy), LSD, DMT (Dimitri), mescaline, and 2C-B. Health Canada also authorized Delic Labs to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The lab has also applied for a Dealer’s License, which would allow it to commercialize its research into psilocybin and associated IP for medical and research purposes.

In a January interview, Delic CEO and co-founder Matt Stang explained that there are 51.5 million Americans who have experienced a mental health condition, and the ongoing pandemic has only exacerbated the crisis. This increase in mental health issues has led to a stronger demand for alternatives to current treatments with lasting outcomes and fewer side effects (https://ibn.fm/ikrCw).

“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Stang added. “We see a strong outlook for Delic with the rollout of 15 additional clinics and an expansion into communities where access to these life-changing treatments is very limited. Delic is well-positioned for growth and profitability in 2022 and beyond.”

The company currently operates 13 wellness clinics across nine states and intends to expand the clinic offering to multiple other locations. The company’s long-term vision for expansion is to have 60-70% of the American population within a 45-minute drive of a clinic. The company also anticipates FDA approval being a reality in the future for compounds like MDMA and psilocybin. 

Once the psychedelic drugs have received some form of FDA approval, “Delic will be the place you can go – you’ll have a clinic in your backyard that you go to for psychedelic medicine treatment, just like any other type of pharmaceutical,” Stang explained in an interview. He further noted that these clinics would offer psychedelic treatments on an in-person basis. Qualified professionals will sit with the patients, walk them through the process, offer them the efficacy they seek, and help them [as a result] change their minds and lives (https://ibn.fm/WfxU1).

For more information, visit the company’s website at www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).